Laubach J P, Paba Prada C E, Richardson P G, Longo D L
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Clin Pharmacol Ther. 2017 Jan;101(1):81-88. doi: 10.1002/cpt.550.
There has been substantial progress in clinical outcomes for patients with multiple myeloma (MM). This encouraging trend derives in large part from the increasing number of effective therapeutic options and the ability because of this to achieve higher quality responses to treatment. The approval of both daratumumab and of elotuzumab in combination with lenalidomide and dexamethasone, in late 2015, was a notable achievement in the field, as daratumumab and elotuzumab represent the first monoclonal antibodies available for use in MM. Given their unique mechanisms of action and favorable side effect profiles, daratumumab and elotuzumab have considerable potential as therapeutic partners with agents in other drug classes and in different clinical settings ranging from newly diagnosed to relapsed disease. This review discusses the development of daratumumab and elotuzumab as well as other monoclonal antibodies currently being evaluated for use in MM.
多发性骨髓瘤（MM）患者的临床治疗结果取得了重大进展。这一令人鼓舞的趋势很大程度上源于有效治疗选择的数量不断增加，以及因此能够实现更高质量的治疗反应。2015年末，达雷妥尤单抗和埃罗妥珠单抗与来那度胺和地塞米松联合使用的获批，是该领域的一项显著成就，因为达雷妥尤单抗和埃罗妥珠单抗是首批可用于MM治疗的单克隆抗体。鉴于其独特的作用机制和良好的副作用谱，达雷妥尤单抗和埃罗妥珠单抗作为治疗伙伴，与其他药物类别以及从新诊断到复发疾病的不同临床环境中的药物联合使用，具有相当大的潜力。本综述讨论了达雷妥尤单抗和埃罗妥珠单抗的研发情况，以及目前正在评估用于MM治疗的其他单克隆抗体。
